Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Adobe
ADBE
|
$593M |
| 2 |
Tesla
TSLA
|
$473M |
| 3 |
NVIDIA
NVDA
|
$470M |
| 4 |
Nike
NKE
|
$403M |
| 5 |
AstraZeneca
AZN
|
$401M |
Top Sells
| 1 |
Amazon
AMZN
|
$897M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$578M |
| 3 |
Moderna
MRNA
|
$457M |
| 4 |
Aon
AON
|
$410M |
| 5 |
Apple
AAPL
|
$401M |
Sector Composition
| 1 | Technology | 20.43% |
| 2 | Healthcare | 20.23% |
| 3 | Consumer Staples | 11.18% |
| 4 | Consumer Discretionary | 9.83% |
| 5 | Industrials | 8.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vodafone
VOD
$28.3B
| $442M | 0.57% |
28,577,732
-1,232,244
| -4% | -$19M |
|
27
Walmart
WMT
$780B
| $424M | 0.55% |
3,040,500
+860,900
| +39% | +$120M |
|
28
Bristol-Myers Squibb
BMY
$96.5B
| $421M | 0.54% |
7,120,925
-185,000
| -3% | -$10.9M |
|
|
29
AstraZeneca
AZN
$249B
| $413M | 0.53% |
6,884,376
+6,682,676
| +3,313% | +$401M |
|
30
Icon
ICLR
$13.8B
| $407M | 0.53% |
1,554,558
-434,260
| -22% | -$114M |
|
31
Gilead Sciences
GILD
$140B
| $384M | 0.5% |
5,500,955
+453,600
| +9% | +$31.7M |
|
32
Exelixis
EXEL
$10B
| $371M | 0.48% |
17,547,501
-535,000
| -3% | -$11.3M |
|
33
Herbalife
HLF
$1.01B
| $371M | 0.48% |
8,748,564
-146,100
| -2% | -$6.19M |
|
34
GSK
GSK
$78.5B
| $360M | 0.46% |
9,414,421
+353,100
| +4% | +$13.5M |
|
|
HZNP
35
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $356M | 0.46% |
3,251,463
-986,200
| -23% | -$108M |
|
36
Vertex Pharmaceuticals
VRTX
$100B
| $343M | 0.44% |
1,891,486
-385,798
| -17% | -$70M |
|
37
CrowdStrike
CRWD
$104B
| $335M | 0.43% |
1,364,430
-35,815
| -3% | -$8.8M |
|
38
Boeing
BA
$179B
| $330M | 0.43% |
+1,498,493
| New | +$330M |
|
39
Alphabet (Google) Class C
GOOG
$2.56T
| $329M | 0.43% |
123,485
+91,800
| +290% | +$245M |
|
40
Pfizer
PFE
$142B
| $321M | 0.41% |
7,457,601
+5,093,860
| +215% | +$219M |
|
41
Palantir
PLTR
$373B
| $312M | 0.4% |
12,959,528
+12,159,128
| +1,519% | +$292M |
|
42
Fortinet
FTNT
$58.9B
| $310M | 0.4% |
1,059,889
-526,395
| -33% | -$154M |
|
43
National Grid
NGG
$67.5B
| $308M | 0.4% |
5,165,277
-1,800
| -0% | -$107K |
|
44
Mastercard
MA
$535B
| $307M | 0.4% |
+882,000
| New | +$307M |
|
45
F5
FFIV
$18B
| $306M | 0.39% |
1,537,862
-361,874
| -19% | -$71.9M |
|
46
Cboe Global Markets
CBOE
$24.7B
| $304M | 0.39% |
2,454,424
-34,500
| -1% | -$4.27M |
|
47
Incyte
INCY
$16.8B
| $303M | 0.39% |
4,411,233
-103,900
| -2% | -$7.15M |
|
48
Netflix
NFLX
$516B
| $296M | 0.38% |
485,100
-9,200
| -2% | -$5.62M |
|
49
Upstart Holdings
UPST
$6.66B
| $292M | 0.38% |
922,900
+254,900
| +38% | +$80.7M |
|
50
Dropbox
DBX
$7.84B
| $280M | 0.36% |
9,593,602
+1,528,369
| +19% | +$44.7M |
|